Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 08 2022
Historique:
pubmed: 28 5 2022
medline: 1 9 2022
entrez: 27 5 2022
Statut: ppublish

Résumé

The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown. We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot results in similar rates of clinical remission and adverse events (AE). The optimal duration of systemic antibiotic therapy, after successful debridement, for soft tissue infections of diabetic patients is unknown. Because of the high recurrence risk, overuse is commonplace. This was a randomized, controlled, non-inferiority pilot trial of cases of diabetic foot infection (excluding osteomyelitis) with the primary outcome of "clinical remission at 2-months follow-up". Among 66 enrolled episodes (17% females; median age 71 years), we randomized 35 to the 10-day arm and 31 to the 20-day arm. The median duration of the parenteral antibiotic therapy was 1 day, with the remainder given orally. In the intention-to-treat population, we achieved clinical remission in 27 (77%) patients in the 10-day arm compared to 22 (71%) in the 20-days arm ( P = 0.57). There were a similar proportion in each arm of AE (14/35 versus 11/31; P = 0.71), and remission in the per-protocol population (25/32 vs 18/27; P = 0.32). Overall, 8 soft tissue DFIs in the 10-day arm and 5 cases in the 20-day arm recurred as a new osteomyelitis [8/35 (23%) versus 5/31 (16%); P = 0.53]. Overall, the number of recurrences limited to the soft tissues was 4 (6%). By multivariate analysis, rates of remission (intention-to-treat population, hazard ratio 0.6, 95%CI 0.3-1.1; per-protocol population 0.8, 95%CI 0.4-1.5) and AE were not significantly different with a 10-day compared to 20-day course. In this randomized, controlled pilot trial, post-debridement antibiotic therapy for soft tissue DFI for 10 days gave similar (and non-inferior) rates of remission and AEs to 20 days. A larger confirmatory trial is under way. ClinicalTrials NCT03615807.

Sections du résumé

BACKGROUND
The optimal duration of antibiotic therapy for soft-tissue infections of the diabetic foot remains unknown.
OBJECTIVE
We determine if antibiotic therapy after debridement for a short (10 days), compared with a long (20 days), duration for soft-tissue infections of the diabetic foot results in similar rates of clinical remission and adverse events (AE).
SUMMARY OF BACKGROUND DATA
The optimal duration of systemic antibiotic therapy, after successful debridement, for soft tissue infections of diabetic patients is unknown. Because of the high recurrence risk, overuse is commonplace.
METHODS
This was a randomized, controlled, non-inferiority pilot trial of cases of diabetic foot infection (excluding osteomyelitis) with the primary outcome of "clinical remission at 2-months follow-up".
RESULTS
Among 66 enrolled episodes (17% females; median age 71 years), we randomized 35 to the 10-day arm and 31 to the 20-day arm. The median duration of the parenteral antibiotic therapy was 1 day, with the remainder given orally. In the intention-to-treat population, we achieved clinical remission in 27 (77%) patients in the 10-day arm compared to 22 (71%) in the 20-days arm ( P = 0.57). There were a similar proportion in each arm of AE (14/35 versus 11/31; P = 0.71), and remission in the per-protocol population (25/32 vs 18/27; P = 0.32). Overall, 8 soft tissue DFIs in the 10-day arm and 5 cases in the 20-day arm recurred as a new osteomyelitis [8/35 (23%) versus 5/31 (16%); P = 0.53]. Overall, the number of recurrences limited to the soft tissues was 4 (6%). By multivariate analysis, rates of remission (intention-to-treat population, hazard ratio 0.6, 95%CI 0.3-1.1; per-protocol population 0.8, 95%CI 0.4-1.5) and AE were not significantly different with a 10-day compared to 20-day course.
CONCLUSIONS
In this randomized, controlled pilot trial, post-debridement antibiotic therapy for soft tissue DFI for 10 days gave similar (and non-inferior) rates of remission and AEs to 20 days. A larger confirmatory trial is under way.
TRIAL REGISTRATION
ClinicalTrials NCT03615807.

Identifiants

pubmed: 35623048
doi: 10.1097/SLA.0000000000005205
pii: 00000658-900000000-93269
pmc: PMC9259031
doi:

Substances chimiques

Anti-Bacterial Agents 0

Banques de données

ClinicalTrials.gov
['NCT03615807']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-238

Informations de copyright

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

All authors do not have any financial conflicts of interest and the funder has not played any decision-making role in this research. The authors report no conflicts of interest.

Références

Clin Infect Dis. 2012 Jun;54(12):e132-73
pubmed: 22619242
BMC Infect Dis. 2018 Aug 2;18(1):361
pubmed: 30068306
J Vasc Surg. 2014 Jan;59(1):220-34.e1-2
pubmed: 24126108
Expert Opin Pharmacother. 2015 Apr;16(6):821-32
pubmed: 25736920
Infect Dis (Lond). 2017 Sep;49(9):716-718
pubmed: 28467136
Diabet Med. 2015 Jun;32(6):748-59
pubmed: 25765225
SAGE Open Med. 2018 May 13;6:2050312118773950
pubmed: 29785265
Int J Infect Dis. 2017 Jun;59:61-64
pubmed: 28450198
Diabetes Obes Metab. 2019 Jun;21(6):1483-1486
pubmed: 30719838
Trials. 2020 Jan 8;21(1):54
pubmed: 31915048
N Engl J Med. 2019 Jan 31;380(5):425-436
pubmed: 30699315
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280
pubmed: 32176444
Diabetes Obes Metab. 2021 Feb;23(2):637-641
pubmed: 33026129
Clin Infect Dis. 1997 Apr;24(4):643-8
pubmed: 9145738
Int J Infect Dis. 2011 Sep;15(9):e601-10
pubmed: 21737333
J Infect. 2012 May;64(5):513-9
pubmed: 22327191
Expert Rev Anti Infect Ther. 2020 Apr;18(4):293-305
pubmed: 32052672
Int J Low Extrem Wounds. 2014 Dec;13(4):263-72
pubmed: 25288579
Diabetes Obes Metab. 2019 Feb;21(2):244-251
pubmed: 30129109
Curr Opin Infect Dis. 2019 Apr;32(2):95-101
pubmed: 30664029
Anaerobe. 2015 Aug;34:8-13
pubmed: 25841893

Auteurs

Truong-Thanh Pham (TT)

Service of Infectious Diseases, Geneva, Switzerland.
Orthopedic Surgery Service, Geneva, Switzerland.

Karim Gariani (K)

Service of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland.

Jean-Christophe Richard (JC)

Orthopedic Surgery Service, Geneva, Switzerland.

Benjamin Kressmann (B)

Service of Infectious Diseases, Geneva, Switzerland.
Orthopedic Surgery Service, Geneva, Switzerland.

François R Jornayvaz (FR)

Service of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland.

Jacques Philippe (J)

Service of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland.

Benjamin A Lipsky (BA)

Service of Infectious Diseases, Geneva, Switzerland.
Department of Medicine, University of Washington, Seattle, WA; and.

Ilker Uçkay (I)

Service of Infectious Diseases, Geneva, Switzerland.
Orthopedic Surgery Service, Geneva, Switzerland.
Infectiology, Balgrist University Hospital, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH